Brazilian city begins first mass vaccination against dengue
Send a link to a friend
[January 04, 2024]
BRASILIA (Reuters) - The city of Dourados in the Brazilian state
of Mato Grosso do Sul on Wednesday began the country's first mass
vaccination against dengue, the city's government said.
The initiative aims to vaccinate around 150,000 residents of the city
between the ages of 4 and 59 using the recently approved Japanese
drugmaker Takeda's vaccine QDENGA.
Distribution started on Wednesday of the first batch of 90,000 doses
already delivered by the Japanese laboratory as part of an agreement
with the city. The vaccination schedule requires a second dose in three
months.
The dengue infection, transmitted by the Aedes aegypti mosquito, causes
a disease that can be mild or have more serious forms, occasionally
leading to death. Symptoms include muscle weakness, drowsiness, refusal
of food and liquids, vomiting, and diarrhea.
By the end of the first week of December, Brazil had registered 1.6
million cases of dengue in 2023, an increase of 15.8% over the same
period last year, according to data from the health ministry. The number
of deaths caused by the infection grew 5.4% in the period to 1,053.
[to top of second column]
|
Aedes aegypti mosquitoes are seen inside Oxitec laboratory in
Campinas, Brazil, February 2, 2016. REUTERS/Paulo Whitaker/File
Photo
Last month, the country's health
ministry announced it would include Takeda's shot in the national
vaccination program of its public health system, known by its local
acronym 'SUS'.
The vaccine will not initially be used in large-scale nationwide,
given its limited supply, instead, it will focus on priority groups
and regions.
The country expects to receive another 5.08 million doses of the
vaccine between February and November.
(Reporting by Ricardo Brito; Writing and additional reporting by
Peter Frontini; Editing by David Gregorio)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |